Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CHUK | O15111 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1357635 | 0.86 | DPP4 (0.33) | DPP4ADORA2AADORA1 | |
| SCHEMBL392017 | 0.82 | TLR8 (0.42) | DPP4ADORA2AADORA1LMNAHSP90AA1 | |
| SCHEMBL11858019 | 0.82 | CYP1A2 (0.32) | DPP4 | |
| SCHEMBL21801328 | 0.78 | TLR8 (0.33) | — | |
| SCHEMBL23998125 | 0.77 | KDM4E (0.32) | HSP90AA1HSP90AB1 | |
| SCHEMBL30322462 | 0.77 | KDM4E (0.32) | HSP90AA1HSP90AB1 | |
| SCHEMBL1356545 | 0.77 | HEXA (0.42) | LMNAHSP90AA1HSP90AB1TDP1 | |
| SCHEMBL14975747 | 0.73 | ALDH1A1 (0.47) | — | |
| SCHEMBL653958 | 0.73 | MEN1 (0.44) | DPP4ADORA2AADORA1NPC1RAB9A | |
| SCHEMBL5261298 | 0.73 | TDP1 (0.42) | DPP4ADORA2AADORA1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230271964-A1 | 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER | NXERA PHARMA UK LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| US-11629147-B2 | Triazolo-pyrimidine compounds and uses thereof | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-04-18 | — | — | US | disclosed |
| CN-112279852-B | Triazolo-pyrimidine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2023-01-17 | — | — | CN | disclosed |
| CN-111635408-B | Triazolo-pyrimidine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20210355104-A1 | ADENOSINE RECEPTOR BINDING COMPOUNDS | NIKANG THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | US | disclosed |
| CN-112279852-A | Triazolo-pyrimidine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2021-01-29 | — | — | CN | disclosed |
| US-20210009600-A1 | TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-01-14 | — | — | US | disclosed |
| US-20210009600-A1 | TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-01-14 | — | — | US | disclosed |
| US-10858365-B2 | Triazolo-pyrimidine compounds and uses thereof | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-12-08 | — | — | US | disclosed |
| US-10858365-B2 | Triazolo-pyrimidine compounds and uses thereof | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-12-08 | — | — | US | disclosed |
| US-20200331918-A1 | TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-10-22 | — | — | US | disclosed |
| US-20200331918-A1 | TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-10-22 | — | — | US | disclosed |
| CN-111635408-A | Triazolo-pyrimidine compounds and uses thereof | 迪哲（江苏）医药有限公司 | 2020-09-08 | — | — | CN | disclosed |
| CN-111601809-A | Triazolo-pyrimidine compounds and uses thereof | 迪哲（江苏）医药有限公司 | 2020-08-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355104-A1 | ADENOSINE RECEPTOR BINDING COMPOUNDS | ADORA2A, ADORA1, ADORA3 | DPP4 3615/4885ADORA2A 1/4885ADORA1 2/4885 |
| US-20210009600-A1 | TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA3, ADORA2B | DPP4 2693/4885ADORA2A 1/4885ADORA1 4/4885 |
| US-11629147-B2 | Triazolo-pyrimidine compounds and uses thereof | ADORA2A, ADORA3, ADORA2B | DPP4 2693/4885ADORA2A 1/4885ADORA1 4/4885 |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | DPP4 1537/4885ADORA2A 1622/4885ADORA1 1287/4885 |
| US-10858365-B2 | Triazolo-pyrimidine compounds and uses thereof | ADORA2A, ADORA3, ADORA2B | DPP4 2693/4885ADORA2A 1/4885ADORA1 4/4885 |
| US-20200331918-A1 | TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA3, ADORA2B | DPP4 2693/4885ADORA2A 1/4885ADORA1 4/4885 |
| US-20230271964-A1 | 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER | ADORA2A, ADORA1, ADORA3 | DPP4 1539/4885ADORA2A 1/4885ADORA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.